secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcellx, Inc. (ACLX)
CIK:        0001786205
Form:       8-K
Filed at:   2022-12-09T23:59:59+00:00
Accession:  0001193125-22-301426
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcellx and Kite (Gilead) partner on CART-ddBCMA; $225M upfront + $100M equity; 100% ORR in Phase 1
--------------------------------------------------------------------------------

- Arcellx receives $225M upfront cash and $100M equity investment from Gilead; eligible for up to $3.9B in milestones.
- Phase 1 trial: 100% ORR (38 pts), 71% CR/sCR, 80% CR/sCR in patients dosed >12 months ago; no Grade≥3 CRS at RP2D.
- Kite to manufacture after tech transfer; 50/50 U.S. profit split; low-to-mid teen royalties ex-U.S.; deal expected to close Q1 2023.
- Gilead purchases 3,478,261 shares at $100M; standstill and registration rights agreed.
- iMMagine-1 Phase 2 pivotal trial initiated; Phase 1 trial of ACLX-002 for AML/MDS also started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/0001193125-22-301426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1786205/000119312522301426/d420020d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-301426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer